<?xml version="1.0" encoding="UTF-8"?>
<itemContainer xmlns="http://omeka.org/schemas/omeka-xml/v5" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://omeka.org/schemas/omeka-xml/v5 http://omeka.org/schemas/omeka-xml/v5/omeka-xml-5-0.xsd" uri="https://neomed.omeka.net/items/browse?tags=Gallium%2F%2Aadministration+%26+dosage%2Fpharmacokinetics%2F%2Atoxicity&amp;sort_field=Dublin+Core%2CTitle&amp;output=omeka-xml" accessDate="2026-03-17T02:13:12-04:00">
  <miscellaneousContainer>
    <pagination>
      <pageNumber>1</pageNumber>
      <perPage>40</perPage>
      <totalResults>1</totalResults>
    </pagination>
  </miscellaneousContainer>
  <item itemId="4764" public="1" featured="1">
    <itemType itemTypeId="1">
      <name>Text</name>
      <description>A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.</description>
      <elementContainer>
        <element elementId="53">
          <name>URL Address</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="59359">
              <text>&lt;a href="http://doi.org/10.1166/jbn.2013.1598" target="_blank" rel="noreferrer noopener"&gt;http://doi.org/10.1166/jbn.2013.1598&lt;/a&gt;</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="55">
          <name>Pages</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="59361">
              <text>1029–1040</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="56">
          <name>Issue</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="59362">
              <text>6</text>
            </elementText>
          </elementTextContainer>
        </element>
        <element elementId="57">
          <name>Volume</name>
          <description/>
          <elementTextContainer>
            <elementText elementTextId="59363">
              <text>9</text>
            </elementText>
          </elementTextContainer>
        </element>
      </elementContainer>
    </itemType>
    <elementSetContainer>
      <elementSet elementSetId="1">
        <name>Dublin Core</name>
        <description>The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.</description>
        <elementContainer>
          <element elementId="50">
            <name>Title</name>
            <description>A name given to the resource</description>
            <elementTextContainer>
              <elementText elementTextId="59351">
                <text>Antitumor efficacy and tolerability of systemically administered gallium acetylacetonate-loaded gelucire-stabilized nanoparticles.</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="45">
            <name>Publisher</name>
            <description>An entity responsible for making the resource available</description>
            <elementTextContainer>
              <elementText elementTextId="59352">
                <text>Journal of biomedical nanotechnology</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="40">
            <name>Date</name>
            <description>A point or period of time associated with an event in the lifecycle of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="59353">
                <text>2013</text>
              </elementText>
              <elementText elementTextId="59354">
                <text>2013-06</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="49">
            <name>Subject</name>
            <description>The topic of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="59355">
                <text>*Lethal Dose 50; Adenocarcinoma/*drug therapy/pathology; Animals; Antineoplastic Agents/administration &amp; dosage/pharmacokinetics/toxicity; Cell Line; Dose-Response Relationship; Drug; Drug Stability; Drug Tolerance; Gallium/*administration &amp; dosage/pharmacokinetics/*toxicity; Humans; Metabolic Clearance Rate; Mice; Nanocapsules/*administration &amp; dosage/chemistry/*toxicity; Nude; Organ Specificity; Tissue Distribution; Treatment Outcome; Triglycerides/chemistry; Tumor</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="39">
            <name>Creator</name>
            <description>An entity primarily responsible for making the resource</description>
            <elementTextContainer>
              <elementText elementTextId="59356">
                <text>Wehrung Daniel; Bi Lipeng; Geldenhuys Werner J; Oyewumi Moses O</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="41">
            <name>Description</name>
            <description>An account of the resource</description>
            <elementTextContainer>
              <elementText elementTextId="59357">
                <text>The widespread clinical success with most gallium compounds in cancer therapy is markedly hampered by lack of tumor specific accumulation, poor tumor permeability and undesirable toxicity to healthy tissues. The aim of this work was to investigate for the first time antitumor mechanism of a new gallium compound (gallium acetylacetonate; GaAcAc) while assessing effectiveness of gelucire-stabilized nanoparticles (NPs) for potential application in gallium-based lung cancer therapy. NPs loaded with GaAcAc (Ga-NPs) were prepared using mixtures of cetyl alcohol with Gelucire 44/14 (Ga-NP-1) or Gelucire 53/13 (Ga-NP-2) as matrix materials. Of special note from this work is the direct evidence of involvement of microtubule disruption in antitumor effects of GaAcAc on human lung adenocarcinoma (A549). In-vivo tolerability studies were based on plasma ALT, creatinine levels and histopathological examination of tissues. The superior in-vivo antitumor efficacy of Ga-NPs over GaAcAc was depicted in marked reduction of tumor weight and tumor volume as well as histological assessment of excised tumors. Compared to free GaAcAc, Ga-NPs showed a 3-fold increase in tumor-to-blood gallium concentrations with minimized overall exposure to healthy tissues. Overall, enhancement of antitumor effects of GaAcAc by gelucire-stabilized NPs coupled with reduced exposure of healthy tissues to gallium would likely ensure desired therapeutic outcomes and safety of gallium-based cancer treatment.</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="43">
            <name>Identifier</name>
            <description>An unambiguous reference to the resource within a given context</description>
            <elementTextContainer>
              <elementText elementTextId="59358">
                <text>&lt;a href="http://doi.org/10.1166/jbn.2013.1598" target="_blank" rel="noreferrer noopener"&gt;10.1166/jbn.2013.1598&lt;/a&gt;</text>
              </elementText>
            </elementTextContainer>
          </element>
          <element elementId="47">
            <name>Rights</name>
            <description>Information about rights held in and over the resource</description>
            <elementTextContainer>
              <elementText elementTextId="59360">
                <text>Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).</text>
              </elementText>
            </elementTextContainer>
          </element>
        </elementContainer>
      </elementSet>
    </elementSetContainer>
    <tagContainer>
      <tag tagId="27742">
        <name>*Lethal Dose 50</name>
      </tag>
      <tag tagId="2">
        <name>2013</name>
      </tag>
      <tag tagId="27743">
        <name>Adenocarcinoma/*drug therapy/pathology</name>
      </tag>
      <tag tagId="123">
        <name>Animals</name>
      </tag>
      <tag tagId="15475">
        <name>Antineoplastic Agents/administration &amp; dosage/pharmacokinetics/toxicity</name>
      </tag>
      <tag tagId="4089">
        <name>Bi Lipeng</name>
      </tag>
      <tag tagId="1410">
        <name>Cell Line</name>
      </tag>
      <tag tagId="32950">
        <name>Department of Pharmaceutical Sciences</name>
      </tag>
      <tag tagId="152">
        <name>Dose-Response Relationship</name>
      </tag>
      <tag tagId="153">
        <name>Drug</name>
      </tag>
      <tag tagId="6140">
        <name>Drug Stability</name>
      </tag>
      <tag tagId="3977">
        <name>Drug Tolerance</name>
      </tag>
      <tag tagId="27744">
        <name>Gallium/*administration &amp; dosage/pharmacokinetics/*toxicity</name>
      </tag>
      <tag tagId="1083">
        <name>Geldenhuys Werner J</name>
      </tag>
      <tag tagId="8">
        <name>Humans</name>
      </tag>
      <tag tagId="15462">
        <name>Journal of biomedical nanotechnology</name>
      </tag>
      <tag tagId="15477">
        <name>Metabolic Clearance Rate</name>
      </tag>
      <tag tagId="861">
        <name>Mice</name>
      </tag>
      <tag tagId="27745">
        <name>Nanocapsules/*administration &amp; dosage/chemistry/*toxicity</name>
      </tag>
      <tag tagId="32954">
        <name>NEOMED College of Pharmacy</name>
      </tag>
      <tag tagId="5908">
        <name>Nude</name>
      </tag>
      <tag tagId="1386">
        <name>Organ Specificity</name>
      </tag>
      <tag tagId="2064">
        <name>Oyewumi Moses O</name>
      </tag>
      <tag tagId="1055">
        <name>Tissue Distribution</name>
      </tag>
      <tag tagId="162">
        <name>Treatment Outcome</name>
      </tag>
      <tag tagId="15479">
        <name>Triglycerides/chemistry</name>
      </tag>
      <tag tagId="1423">
        <name>Tumor</name>
      </tag>
      <tag tagId="2060">
        <name>Wehrung Daniel</name>
      </tag>
    </tagContainer>
  </item>
</itemContainer>
